Effects of selected histamine H3 receptor antagonists on tele-methylhistamine levels in rat cerebral cortex

• Published in: Biochemical pharmacology Vol. 57; no. 9; pp. 1059 - 1066
• Main Authors: YATES, S. L, TEDFORD, C. E, GREGORY, R, PAWLOWSKI, G. P, HANDLEY, M. K, BOYD, D. L, HOUGH, L. B
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Science 01.05.1999
• Subjects: Analysis of Variance; Animals; Biological and medical sciences; Cerebral Cortex - drug effects; Cerebral Cortex - metabolism; Gas Chromatography-Mass Spectrometry; Histamine and antagonists. Allergy; Histamine Antagonists - pharmacology; Male; Medical sciences; Methylhistamines - metabolism; Pharmacology. Drug treatments; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Receptors, Histamine H3 - metabolism; Drug combination; Cerebral cortex; Intraperitoneal administration; Rat; MAO inhibitor; Rodentia; Central nervous system; Gas chromatography; Histamine; Vertebrata; Mammalia; Animal; Drug interaction; Antagonist; Pargyline; Mass spectrometry; H3 Histamine receptor
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/S0006-2952(98)00378-5

The H3 antagonist thioperamide is thought to act on brain H3 autoreceptors to increase both the release and metabolism of neuronal histamine (HA). Our studies investigated the effects of several new brain-penetrating H3 antagonists on rat cerebral cortical levels of the HA metabolite tele-methylhistamine (t-MH). Animals were pretreated with H3 antagonists (0.3 to 30 mg/kg; 1-4 hr; i.p.) in the presence or absence of the monoamine oxidase inhibitor pargyline to prevent metabolism of t-MH. Cortical t-MH levels were measured by both radioimmunoassay (RIA) and gas chromatography-mass spectrometry (GC-MS). Pargyline (60 mg/kg; 1 hr; i.p.) produced an approximately 2-fold increase in t-MH levels as measured by either GC-MS or RIA. Thioperamide (+/- pargyline) increased t-MH levels as measured by both GC-MS and RIA. In contrast, neither 5-cyclohexyl-1-(4-imidazol-4-ylpiperidyl)pentan-1-one (GT-2016) (+/- pargyline), 4-(6-cyclohexylhex-cis-3-enyl)imidazole (GT-2227) (+/- pargyline), nor clobenpropit (minus pargyline) increased t-MH levels as measured by GC-MS. A good agreement was found between t-MH levels as determined by either RIA or GC-MS except after treatment with GT-2016, which increased apparent t-MH brain levels according to the former but not the latter method. Subsequent studies suggest the in vivo formation of a GT-2016 metabolite, which can cross-react in the t-MH RIA. Although all H3 receptor antagonists studied to date seem capable of enhancing brain HA release, only thioperamide presently was found to enhance cortical t-MH levels. Thus, H3 receptor antagonists may differentially affect HA release and turnover, and brain t-MH levels may not be reliable predictors of H3 agonist, partial agonist, or antagonist in vivo activity.